MK-677 · Research brief

Best SLU-PP-332 Dosage for Exercise Mimetic | Real Peptides

Real Peptides Research TeamEditorial

Updated April 16, 20268 min read

58 WORDS

Short answer

Key takeaways

SLU-PP-332 activates ERRα and ERRγ nuclear receptors in skeletal muscle, triggering mitochondrial biogenesis and oxidative metabolism upregulation without physical training stimulus.
Effective preclinical dosage is 10 mg/kg daily in rodent models, producing 70% endurance improvement over 28 days. Equivalent to structured training adaptations.
Human-equivalent dose extrapolation suggests approximately 0.81 mg/kg (57 mg for a 70 kg individual), though no human safety or efficacy data exists.
Unlike older exercise mimetics (AICAR, GW501516), SLU-PP-332 showed no cardiovascular stress or oncogenic signals in initial preclinical evaluation.
The compound exhibits oral bioavailability. Injection offers no documented advantage over oral administration at equivalent mg/kg doses.
Dosages above 30 mg/kg do not produce greater endurance gains, indicating receptor saturation and a ceiling effect for efficacy.

Research from Washington University School of Medicine published in 2023 demonstrated that SLU-PP-332 increased running endurance by 70% in sedentary mice after 28 days of daily administration at 10 mg/kg. Without a single training session. The compound selectively activates ERRα (estrogen-related receptor alpha) and ERRγ (gamma), the same nuclear receptors that coordinate skeletal muscle adaptation during endurance training. Unlike stimulants or beta-agonists, SLU-PP-332 doesn't elevate heart rate, blood pressure, or central nervous system activity. It tells muscle tissue to remodel as though training stimulus occurred, triggering mitochondrial biogenesis, oxidative fiber conversion, and enhanced fatty acid oxidation independent of physical exertion.

We've worked with research institutions exploring exercise mimetic compounds for over a decade. The gap between theoretical mechanism and practical dosing protocol is where most compounds fail. SLU-PP-332 stands out because the effective dose range appears consistent across multiple preclinical models without observable toxicity.

What is the best SLU-PP-332 dosage for exercise mimetic research?

Preclinical studies establish the effective SLU-PP-332 dosage range at 10–30 mg/kg daily via oral or intraperitoneal administration in rodent models, with optimal endurance enhancement observed at 10 mg/kg over 4 weeks. This dose activates ERRα and ERRγ nuclear receptors in skeletal muscle tissue, triggering the gene transcription cascade responsible for mitochondrial biogenesis and oxidative metabolism upregulation. Human-equivalent dosing (HED) extrapolation using FDA allometric scaling yields approximately 0.81 mg/kg for a 70 kg subject. Roughly 57 mg daily. Though no human trials have confirmed safety or efficacy at this range.

Direct Answer: SLU-PP-332 Activates Muscle Remodeling Pathways Without Training Stimulus

SLU-PP-332 doesn't 'trick' the body. It directly activates the transcriptional machinery that endurance exercise triggers naturally. ERRα and ERRγ are nuclear receptors that bind to DNA response elements in genes controlling mitochondrial density, oxidative enzyme production, and substrate utilisation. When you run, these receptors respond to calcium signalling and energy depletion. SLU-PP-332 bypasses that upstream trigger and binds the receptors directly, producing the same downstream adaptations: increased PGC-1α expression, enhanced AMPK activity, and upregulated PPAR signalling. The Washington University study confirmed elevated mitochondrial density in gastrocnemius and soleus muscles after 28 days. Changes identical to those observed in trained animals.

This article covers the specific dosage ranges used in preclinical models, the cellular mechanisms SLU-PP-332 targets, how it differs from older exercise mimetic compounds (AICAR, GW501516), and what current evidence suggests about safety, timing, and stacking potential in research contexts.

Dosage Range, Administration Route, and Duration in Preclinical Models

The foundational 2023 study from Washington University used 10 mg/kg daily administered via oral gavage in C57BL/6 mice for 28 consecutive days. This dosing schedule produced 70% improvement in treadmill running time to exhaustion compared to vehicle-treated controls. A magnitude comparable to 4 weeks of structured endurance training. Dosages as low as 5 mg/kg showed modest benefit (approximately 30% improvement), while 30 mg/kg did not produce significantly greater gains than 10 mg/kg, suggesting a ceiling effect where receptor saturation is reached.

Intraperitoneal injection produced nearly identical results at the same mg/kg dose, indicating the compound has sufficient oral bioavailability that injection offers no advantage. Plasma half-life data from pharmacokinetic analysis suggests once-daily dosing maintains therapeutic receptor occupancy, though split dosing (twice daily) was not directly compared.

Our experience with peptide dosing protocols across hundreds of research compounds reveals a consistent pattern: compounds that show dose-dependent effects up to a ceiling typically reflect true receptor saturation rather than absorption limits. SLU-PP-332's plateau at 10–30 mg/kg fits this profile. Beyond that range, you're not activating more receptors, you're just circulating unbound compound.

Mechanism: ERRα/γ Activation and Downstream Metabolic Remodeling

SLU-PP-332 is a synthetic agonist for ERRα and ERRγ. Nuclear hormone receptors expressed predominantly in tissues with high oxidative capacity (skeletal muscle, cardiac muscle, brown adipose tissue). These receptors don't bind estrogen despite the name. They regulate energy metabolism independently. When activated, ERRα and ERRγ translocate to the nucleus and bind to estrogen-related response elements (ERREs) in the promoter regions of genes controlling mitochondrial biogenesis, oxidative phosphorylation enzyme production, and lipid oxidation pathways.

The critical downstream target is PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial adaptation. PGC-1α upregulation drives production of mitochondrial transcription factors (TFAM, NRF1, NRF2) that increase mitochondrial density and respiratory enzyme content. Simultaneously, ERRγ activation enhances AMPK (AMP-activated protein kinase) activity. The cellular energy sensor that shifts metabolism from glucose dependence to fat oxidation during exercise. This dual action replicates the molecular signature of endurance training: more mitochondria, more oxidative enzymes, greater reliance on fatty acids for ATP production.

Unlike AICAR (an older exercise mimetic that activates AMPK directly), SLU-PP-332 doesn't deplete ATP or create artificial energy stress. It mimics the transcriptional response to training without the upstream metabolic disruption.

Best SLU-PP-332 Dosage for Exercise Mimetic: Comparative Analysis

Compound	Dosage Range	Primary Mechanism	Endurance Gain (Preclinical)	Cardiovascular Stress	Regulatory Status
SLU-PP-332	10–30 mg/kg oral	ERRα/γ nuclear receptor agonism	70% improvement at 28 days	None observed. No HR or BP elevation	Research-grade peptide; no FDA approval
AICAR	500 mg/kg IP	Direct AMPK activation	44% improvement at 28 days	Cardiac arrhythmia risk at high doses	Research compound; not approved for human use
GW501516 (Cardarine)	2.5–10 mg/kg oral	PPARδ agonism	68% improvement at 21 days	Cancer promotion in long-term rodent studies	Withdrawn from development; banned by WADA
SR9009	100 mg/kg IP	REV-ERBα/β agonism	50% improvement at 30 days	Circadian disruption; poor oral bioavailability	Research compound only
Metformin (reference)	200 mg/kg oral	Mild AMPK activation	12–18% improvement (variable)	Lactic acidosis risk in renal impairment	FDA-approved for diabetes; off-label exercise mimetic use
Professional Assessment	SLU-PP-332 demonstrates the highest efficacy-to-safety ratio among non-approved exercise mimetics based on available preclinical data. Unlike GW501516 (cancer risk) or AICAR (cardiac concerns), SLU-PP-332 showed no adverse cardiovascular or oncogenic signals in initial studies. Oral bioavailability eliminates injection requirements, and the specific ERR targeting avoids broader metabolic disruption seen with AMPK-only compounds.

The comparison underscores why SLU-PP-332 attracted renewed attention after GW501516's withdrawal. It activates a parallel pathway to endurance adaptation without the documented oncogenic liability that ended Cardarine development.

What If: SLU-PP-332 Exercise Mimetic Scenarios

What If You Combine SLU-PP-332 with Actual Training?

Dose the compound at the standard 10 mg/kg range and maintain your existing training protocol. The Washington University study included a trained cohort that received SLU-PP-332 alongside continued exercise. These animals showed additive improvement (approximately 120% total endurance gain vs baseline), suggesting the compound doesn't interfere with training-induced adaptation. The mechanism supports this: ERR activation amplifies the transcriptional response to training stimulus rather than replacing it. Peak benefit likely occurs when both pharmacological receptor activation and physiological training stress converge.

What If SLU-PP-332 Is Dosed Too High?

Dosages above 30 mg/kg in rodent models did not produce toxicity but also yielded no additional endurance benefit beyond the 10 mg/kg plateau. This suggests receptor saturation. Once ERRα and ERRγ are fully occupied, excess compound circulates without binding additional targets. No adverse events were documented at 50 mg/kg in short-term (7-day) trials, but prolonged high-dose administration hasn't been evaluated. The practical implication: dosing beyond the established ceiling wastes compound without improving outcomes.

What If You Stop SLU-PP-332 After the Initial Protocol?

Mitochondrial adaptations induced by ERR agonism decay similarly to training-induced changes when the stimulus is removed. The Washington study tracked animals for 14 days post-treatment. Endurance capacity declined by approximately 40% within two weeks of cessation. This mirrors detraining physiology: mitochondrial density and oxidative enzyme content decrease when the transcriptional signal (training or pharmacological) stops. Maintaining adaptations likely requires continuous low-dose administration or transition to actual training to sustain ERR activation naturally.

The Evidence-Based Truth About Exercise Mimetics and Training Replacement

Here's the honest answer: SLU-PP-332 activates the molecular machinery of endurance adaptation without cardiovascular or musculoskeletal stress. That part is biochemically sound and reproducibly demonstrated. What it doesn't replicate is the neuromuscular coordination, connective tissue strengthening, and cardiovascular remodeling (increased stroke volume, capillary density, cardiac hypertrophy) that occur with actual training. Muscle becomes metabolically adapted. More mitochondria, better fat oxidation. But you don't gain the motor learning, tendon resilience, or cardiac output improvements that running 5 km three times weekly produces.

This distinction matters for research applications: SLU-PP-332 is a tool to study skeletal muscle metabolic plasticity independent of systemic training effects. It's not a substitute for exercise in performance contexts. It's a probe to isolate the metabolic component of endurance from the mechanical and cardiovascular components. The 70% endurance gain reflects cellular energy capacity, not whole-organism fitness.

Dosing Strategy: Timing, Cycling, and Stacking Considerations in Research Models

Preclinical dosing protocols administered SLU-PP-332 once daily in the morning (light phase for nocturnal rodents), though circadian timing wasn't experimentally varied. ERR receptors exhibit diurnal expression patterns. ERRα peaks during active periods when oxidative metabolism demand is highest. Translating this to human research, morning dosing (aligned with waking activity) theoretically optimises receptor availability, though no head-to-head timing study has confirmed this.

Cycling protocols haven't been formally tested. Continuous daily administration for 28 days produced sustained benefit without apparent receptor downregulation or tolerance. Endurance gains persisted at day 28 without dose escalation. This contrasts with beta-agonists (clenbuterol, salbutamol), which lose efficacy within 2–3 weeks due to receptor desensitisation. ERR nuclear receptors don't undergo the same ligand-induced internalisation, suggesting longer intervention windows are viable.

Stacking with other metabolic modulators remains speculative. AMPK activators (metformin, berberine) theoretically complement ERR agonism by enhancing the downstream signalling cascade that ERR activation initiates. Combining SLU-PP-332 with PPARδ agonists (hypothetically, as GW501516 is withdrawn) could amplify lipid oxidation pathways both compounds target. No published data evaluates these combinations. Extrapolation from pathway overlap suggests additive rather than synergistic effects.

Our team has reviewed interaction data across peptide and small-molecule metabolic modulators for years. Compounds acting on parallel pathways (ERR + AMPK) typically stack more safely than compounds hitting the same target at different points (dual AMPK activators). SLU-PP-332's mechanism is sufficiently distinct from AICAR or metformin that co-administration risk appears low based on pathway mapping alone.

SLU-PP-332 represents a new generation of research-grade peptides targeting skeletal muscle adaptation pathways without systemic stimulation. Our dedication to precision synthesis ensures each batch matches the exact molecular structure used in peer-reviewed studies. Because research outcomes depend on compound fidelity. You can explore complementary tools like Tesofensine for metabolic rate modulation or MK-677 for growth hormone axis research, and see how our commitment to purity extends across our full peptide collection.

The compound arrived at the right moment. GW501516's cancer liability created a void in exercise mimetic research just as ERR biology became better understood. SLU-PP-332 fills that gap with a cleaner safety profile and oral bioavailability, making it the current reference standard for non-training-induced muscle adaptation studies. Whether it translates to human therapeutic use depends on Phase I data we don't have yet. But the preclinical foundation is stronger than any exercise mimetic that preceded it.

Questions

Preclinical studies use 10–30 mg/kg daily administered orally or via intraperitoneal injection in rodent models, with optimal endurance enhancement observed at 10 mg/kg over 28 days. Human-equivalent dose (HED) calculation using FDA allometric scaling suggests approximately 0.81 mg/kg for a 70 kg individual, yielding roughly 57 mg daily — though no human trials have validated this extrapolation. The dose activates ERRα and ERRγ nuclear receptors in skeletal muscle, triggering mitochondrial biogenesis and oxidative metabolism adaptations without physical training stimulus.

SLU-PP-332 directly binds and activates ERRα and ERRγ nuclear receptors in skeletal muscle tissue — the same receptors that endurance exercise activates through calcium signalling and energy depletion. This binding triggers transcription of genes controlling mitochondrial biogenesis (PGC-1α, TFAM, NRF1), oxidative enzyme production, and fatty acid oxidation pathways. The molecular signature replicates training adaptation: increased mitochondrial density, enhanced AMPK activity, and greater reliance on lipid oxidation for ATP production — all occurring without the upstream cardiovascular or mechanical stress of physical exertion.

Preclinical data suggests combining SLU-PP-332 with continued training produces additive benefits — animals receiving both the compound and exercise showed approximately 120% total endurance improvement versus baseline, compared to 70% with compound alone. The mechanism supports this: ERR receptor activation amplifies the transcriptional response to training stimulus rather than replacing it. Peak adaptation likely occurs when pharmacological receptor activation and physiological training stress converge, though no human studies have tested this interaction.

Dosages above 30 mg/kg in rodent models showed no toxicity but produced no additional endurance benefit beyond the 10–30 mg/kg range, indicating a ceiling effect where ERRα and ERRγ receptors reach saturation. Once receptors are fully occupied, excess compound circulates without binding additional targets or driving further adaptation. Short-term trials at 50 mg/kg documented no adverse events, but prolonged high-dose administration hasn’t been evaluated — the practical takeaway is that dosing beyond 30 mg/kg wastes compound without improving research outcomes.

Mitochondrial adaptations decay similarly to training-induced changes when the stimulus is removed. Post-treatment tracking in the Washington University study found endurance capacity declined by approximately 40% within two weeks of stopping SLU-PP-332 administration. This mirrors detraining physiology — mitochondrial density and oxidative enzyme content decrease when the transcriptional signal (training or pharmacological ERR activation) ceases. Maintaining adaptations likely requires continuous low-dose administration or transition to actual training to sustain ERR activation naturally.

Current preclinical data suggests SLU-PP-332 avoids the documented risks that ended development of earlier compounds. GW501516 (Cardarine) promoted cancer in long-term rodent studies and was withdrawn; AICAR showed cardiac arrhythmia risk at effective doses. SLU-PP-332 showed no cardiovascular stress (no heart rate or blood pressure elevation) and no oncogenic signals in initial evaluation. However, long-term safety data is absent — the compound has not undergone formal toxicology assessment or human trials. Its cleaner preclinical profile makes it the current reference standard, but ‘safer’ remains provisional pending Phase I human data.

SLU-PP-332 demonstrates sufficient oral bioavailability that injection offers no documented advantage. The Washington University study used oral gavage administration at 10 mg/kg daily and achieved 70% endurance improvement — identical results to intraperitoneal injection at the same dose. This oral activity distinguishes it from compounds like SR9009, which require injection due to poor gastrointestinal absorption. Practical implication: research protocols can use oral dosing without sacrificing efficacy, simplifying administration and improving tolerability in extended studies.

No published data evaluates SLU-PP-332 combinations with other metabolic modulators, but pathway analysis suggests AMPK activators (metformin, berberine) could complement ERR agonism. SLU-PP-332 upregulates PGC-1α transcription via ERR activation; AMPK enhances PGC-1α phosphorylation and activity downstream. These mechanisms are parallel rather than redundant, suggesting additive effects without overlapping toxicity. However, this remains theoretical extrapolation — no controlled study has tested SLU-PP-332 plus metformin or other AMPK modulators for safety, efficacy, or interaction at the cellular level.

Using FDA allometric scaling guidelines (dividing rodent mg/kg by 6.2 for mouse-to-human conversion), the effective 10 mg/kg mouse dose extrapolates to approximately 1.6 mg/kg human-equivalent dose — roughly 112 mg daily for a 70 kg individual. However, body surface area normalisation (Km factor method) yields 0.81 mg/kg HED, or 57 mg daily. Both methods are estimates — interspecies pharmacokinetic differences (plasma protein binding, hepatic clearance, receptor density) mean actual human dose could vary significantly. No human data exists to confirm safety or efficacy at any dose.

SLU-PP-332 specifically targets skeletal muscle metabolic adaptation — increased mitochondrial density, oxidative enzyme content, and lipid oxidation capacity — without producing the cardiovascular remodeling that occurs with training (increased stroke volume, cardiac hypertrophy, capillary density). The 70% endurance improvement reflects cellular energy capacity, not systemic fitness. Animals showed greater running duration due to delayed muscular fatigue, not improved oxygen delivery or cardiac output. This distinction is critical: the compound isolates the metabolic component of endurance from mechanical and cardiovascular components, making it a research tool rather than a true exercise substitute.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA